50. Dermatomyositis
157 clinical trials,   207 drugs   (DrugBank: 76 drugs),   47 drug target genes,   142 drug target pathways

Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-006311-21-CZ
(EUCTR)
19/11/200915/09/2009A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis - Polymyositis and dermatomyositis
MedDRA version: 9.1;Level: LLT;Classification code 10036102;Term: Polymyositis
MedDRA version: 9.1;Classification code 10012503;Term: Dermatomyositis
Product Name: BAF312 5 mg tablet
Product Code: BAF312
Product Name: BAF312 4mg tablet
Product Code: BAF312
Product Name: BAF312 1mg tablet
Product Code: BAF312
Product Name: BAF312 0.25mg tablet
Product Code: BAF312
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
45Hungary;United Kingdom;Czech Republic;Sweden